Gland Pharma Reports Strong Q2 FY26 Results, Driven by US Launches and Capacity Expansion
Gland Pharma reported strong Q2 FY26 consolidated revenue growth of 6% YoY and PAT growth of 12% YoY. Key drivers include new US product launches, increased R&D, and expanded GLP-1 capacity, with Cenexi upgrades progressing despite a temporary shutdown impact.
The announcement details the company's Q2 FY26 financial performance, which showed strong growth. Furthermore, it provides comprehensive updates on key strategic initiatives, including product launches, R&D, capacity expansion, and international operations. These details offer significant insight into the company's current health and future growth drivers, making the announcement highly impactful for investors.
The company reported positive year-on-year growth in revenue, gross profit, EBITDA, and PAT for both Q2 FY26 and 6M FY26. Strategic initiatives like new product launches in the US, significant R&D investments, capacity expansion for GLP-1s, and progress in co-development partnerships indicate strong future growth prospects. While Cenexi experienced a temporary impact from a planned shutdown, the upgrades and recovery plan are on track, reinforcing a positive outlook.
* Gland Pharma Limited announced its Investor Presentation for Q2 FY26 Financial Results, highlighting robust performance and strategic advancements.
* Consolidated Financial Highlights for Q2 FY26: * Revenue from operations increased by 6% year-on-year (YoY) to ₹1,486.9 crore (₹14,869 million). * Gross Profit rose by 12% YoY to ₹933.1 crore (₹9,331 million), with a gross profit margin of 63%. * EBITDA grew by 6% YoY to ₹313.9 crore (₹3,139 million), maintaining an EBITDA margin of 21%. * Profit After Tax (PAT) increased by 12% YoY to ₹183.7 crore (₹1,837 million), with a PAT margin of 12%.
* Consolidated Financial Highlights for 6M FY26: * Revenue from operations increased by 7% YoY to ₹2,992.5 crore (₹29,925 million). * PAT surged by 30% YoY to ₹399.2 crore (₹3,992 million).
* Base Business (Gland) Highlights: * Revenue from operations for Q2 FY26 grew by 1% YoY to ₹1,076.7 crore (₹10,767 million). * PAT for Q2 FY26 increased by 7% YoY to ₹305.5 crore (₹3,055 million).
* Key Business Updates: * R&D Expenses: Total R&D expenses were ₹61.4 crore (₹614 million) in Q2 FY26, representing 5.8% of revenue. * New Launches: Seven molecules were launched in the USA during the quarter, including Daptomycin-RTU and Sumatriptan. * Filings and Approvals: Six ANDAs were filed and five were approved in Q2 FY26, contributing to a cumulative total of 378 ANDA filings in the U.S. (329 approved, 49 pending). * Complex Pipeline: Six in-house complex injectables have been launched, with three more in line for approval. * Co-development Partnerships: Fifteen products are in co-development, with commercialization expected to begin in FY28. * Ready-to-Use (RTU) Bags: 20 RTU infusion bag products filed, 14 approved, and 10 more under development, targeting a US market opportunity of approximately $659 million. * GLP-1s, Pens, and Cartridges: Capacity is being aggressively increased from ~40 million to 140 million units following the launch of Liraglutide in Q4 FY25.
* Cenexi Updates: * Revenues and margins were impacted in Q2 FY26 due to a planned shutdown for infrastructure and equipment upgrades at the Fontenay facility. The GMP certificate for Fontenay was renewed through the end of CY2026. * Production at Fontenay is on track with improved order shipments following the commissioning of a new high-speed ampoule line. * Hérouville facility saw ramp-up of an inactivated vaccine and a sterile ophthalmic gel. * Qualification of two new lyophilizers at Braine-l'Alleud & Osny is underway and expected to be completed by the end of 2025.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.